Susie W Cohn, MD
Gastroenterology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 18 years
- Graduated 2008
Offices
2 locations · East Bay Center for Digestive Health Medical Associates Inc · Alameda Health System
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Highland Hospital. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cohn’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A111820 · Current
Licensed to practise in California · since 2010 · expires 2028-04-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- The Oakland CA Endosurgery ASC, LP dba East Bay EndosurgeryAmbulatory Surgery Center · Oakland, CA6.1% owner since 2006 · accredited by AAAHCAccreditation Renewed5 inspections, 2 with deficiencies · last 2025-12-15: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$130,349
Medicare paid this office $130,349 for 576 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 266 | $64,223 | $240 |
| Return visit (30+ min) | 133 | $13,296 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 135 | $12,231 | $88 |
| New patient visit (45+ min) | 55 | $7,089 | $129 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 26 | $5,274 | $203 |
See all 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 266 | $64,223 | $240 |
| Return visit (30+ min) | 133 | $13,296 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 135 | $12,231 | $88 |
| New patient visit (45+ min) | 55 | $7,089 | $129 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 26 | $5,274 | $203 |
| Long return visit (40+ min) | 26 | $4,572 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,916 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,809 | $159 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $2,773 | $146 |
| Biopsy of large bowel using a flexible endoscope | 40 | $2,690 | $67 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,626 | $90 |
Procedures Medicare counted
| Colonoscopy | 131 | More than 86% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 138 | More than 83% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 104 | 108 | 200 | 213 | 178 | 268 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | 85 | 118 | 126 | 133 | 139 |
| Biopsy of large bowel using a flexible endoscope | 42 | 30 | 42 | 22 | 33 | 40 |
| Diagnostic exam of large bowel using a flexible endoscope | 18 | 22 | 29 | 25 | 23 | 19 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | 19 | – | – | – | 18 |
| Destruction of polyp or growth of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | – | – | 19 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
576 Original Medicare patients in 2024. Average age 72 · Under 65 9% · 85 and older 6% · Women 59% · Also on Medicaid 59% · Health risk score 1.29. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 67% · Diabetes 32% · Chronic kidney disease 21% · Depression 20% · Coronary heart disease 16% · Cancer 16% · Atrial fibrillation 12% · Heart failure 10% · COPD 10% · Stroke 6% · Dementia 5%.
The office billed $655,282, Medicare allowed $164,239 and paid $130,349; for 881 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 576 | 881 | 72 | 1.29 | $655,282 | $130,349 |
| 2023 | 637 | 1,012 | 72 | 1.44 | $599,985 | $120,526 |
| 2022 | 806 | 1,183 | 72 | 1.30 | $683,807 | $140,684 |
| 2021 | 717 | 1,078 | 71 | 1.23 | $639,384 | $140,364 |
| 2020 | 604 | 992 | 71 | 1.61 | $480,811 | $116,228 |
| 2019 | 633 | 958 | 72 | 1.36 | $456,029 | $114,089 |
| 2018 | 785 | 1,224 | 72 | 1.49 | $594,643 | $137,573 |
| 2017 | 682 | 1,191 | 72 | 1.49 | $608,022 | $144,137 |
| 2016 | 328 | 679 | 70 | 1.36 | $399,796 | $84,405 |
| 2015 | 328 | 670 | 71 | 1.49 | $398,813 | $91,089 |
| 2014 | 82 | 171 | 70 | 1.25 | $99,812 | $23,456 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 177 | $40,999 | $230 |
| Return visit (30+ min) | 199 | $15,656 | $71 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 130 | $12,636 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $8,609 | $154 |
| New patient visit (45+ min) | 90 | $7,944 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $6,434 | $105 |
| Biopsy of large bowel using a flexible endoscope | 33 | $3,444 | $104 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 18 | $3,296 | $183 |
| Long return visit (40+ min) | 22 | $3,055 | $105 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | $2,807 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,333 | $70 |
| New patient visit (30+ min) | 12 | $906 | $76 |
| Short return visit (20+ min) | 16 | $904 | $57 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $52 | $4 |
2022: 16 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 212 | $46,137 | $217 |
| Return visit (30+ min) | 262 | $23,131 | $78 |
| New patient visit (45+ min) | 170 | $15,247 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 125 | $11,164 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,471 | $175 |
| Long return visit (40+ min) | 37 | $5,635 | $134 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 19 | $3,804 | $200 |
| Diagnostic exam of large bowel using a flexible endoscope | 25 | $3,704 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,612 | $90 |
| Destruction of polyp or growth of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $3,496 | $184 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $2,983 | $199 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,913 | $101 |
| Biopsy of large bowel using a flexible endoscope | 22 | $1,454 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,445 | $63 |
| Short return visit (20+ min) | 21 | $1,259 | $57 |
| New patient visit (30+ min) | 13 | $799 | $61 |
2021: 10 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 199 | $43,708 | $219 |
| Return visit (30+ min) | 277 | $33,282 | $105 |
| New patient visit (45+ min) | 148 | $16,329 | $110 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 112 | $10,292 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,776 | $178 |
| Biopsy of large bowel using a flexible endoscope | 41 | $3,808 | $91 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $3,302 | $114 |
| Long return visit (40+ min) | 14 | $2,638 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,603 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $970 | $65 |
2020: 14 services
| Return visit (30+ min) | 254 | $28,588 | $90 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 107 | $25,130 | $233 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $9,238 | $185 |
| New patient visit (45+ min) | 78 | $8,298 | $106 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | $8,053 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $7,998 | $95 |
| New patient visit (30+ min) | 59 | $4,431 | $75 |
| Biopsy of large bowel using a flexible endoscope | 30 | $3,366 | $112 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $3,269 | $149 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 17 | $3,168 | $186 |
| Long return visit (40+ min) | 14 | $2,186 | $121 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,946 | $102 |
| Short return visit (20+ min) | 30 | $1,729 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,329 | $66 |
2019: 10 services
| Return visit (30+ min) | 272 | $30,535 | $94 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 103 | $23,663 | $228 |
| New patient visit (45+ min) | 145 | $17,695 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $5,968 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,941 | $161 |
| Biopsy of large bowel using a flexible endoscope | 41 | $5,530 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $5,375 | $93 |
| Short return visit (20+ min) | 53 | $3,006 | $56 |
| Diagnostic exam of large bowel using a flexible endoscope | 18 | $2,957 | $164 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,017 | $92 |
2018: 16 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 173 | $37,343 | $216 |
| New patient visit (45+ min) | 179 | $19,540 | $109 |
| Return visit (30+ min) | 166 | $15,840 | $86 |
| Short return visit (20+ min) | 168 | $11,354 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $9,912 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,641 | $180 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 91 | $8,226 | $89 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $2,870 | $144 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 13 | $2,735 | $210 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,527 | $211 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $2,031 | $107 |
| Biopsy of large bowel using a flexible endoscope | 31 | $1,768 | $57 |
| Long return visit (40+ min) | 11 | $1,707 | $114 |
| Breath test analysis for helicobacter pylori | 19 | $1,630 | $82 |
| New patient visit (30+ min) | 22 | $1,501 | $68 |
| Administration of drug for helicobacter pylori | 19 | $190 | $10 |
2017: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 148 | $32,411 | $215 |
| New patient visit (45+ min) | 211 | $24,935 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $15,889 | $175 |
| Return visit (30+ min) | 119 | $11,839 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 113 | $10,707 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,674 | $91 |
| Short return visit (20+ min) | 89 | $6,833 | $67 |
| Long return visit (40+ min) | 47 | $5,630 | $97 |
| Biopsy of large bowel using a flexible endoscope | 42 | $3,631 | $86 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $3,149 | $150 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,113 | $195 |
| New patient visit (30+ min) | 30 | $2,521 | $84 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,500 | $100 |
| Breath test analysis for helicobacter pylori | 13 | $1,177 | $91 |
| Administration of drug for helicobacter pylori | 13 | $137 | $11 |
2016: 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 97 | $21,434 | $221 |
| New patient visit (45+ min) | 95 | $11,056 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $7,893 | $172 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 72 | $7,655 | $101 |
| Return visit (30+ min) | 63 | $6,225 | $86 |
| Biopsy of large bowel using a flexible endoscope | 52 | $5,531 | $106 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,041 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,037 | $89 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $2,597 | $137 |
| Long return visit (40+ min) | 18 | $2,595 | $124 |
| Short return visit (20+ min) | 36 | $2,571 | $56 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,316 | $110 |
| Breath test analysis for helicobacter pylori | 12 | $1,079 | $90 |
| Administration of drug for helicobacter pylori | 12 | $126 | $11 |
2015: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 95 | $24,576 | $259 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,945 | $174 |
| New patient visit (45+ min) | 72 | $9,397 | $131 |
| Biopsy of large bowel using a flexible endoscope | 55 | $7,212 | $131 |
| Return visit (30+ min) | 62 | $7,124 | $91 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 68 | $6,300 | $90 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $4,185 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,128 | $90 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 17 | $3,777 | $222 |
| New patient visit (60+ min) | 19 | $3,055 | $161 |
| Short return visit (20+ min) | 37 | $2,624 | $64 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,616 | $108 |
| New patient visit (30+ min) | 13 | $1,162 | $89 |
2014: 7 services
| Biopsy of large bowel using a flexible endoscope | 24 | $3,853 | $161 |
| New patient visit (45+ min) | 25 | $3,525 | $141 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $3,053 | $254 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,679 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,607 | $174 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,196 | $70 |
| Return visit (30+ min) | 11 | $1,054 | $96 |
Medicaid work
$7,849 in 2024
Medicaid paid $7,849 for 944 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COLONOSCOPY W/LESION REMOVAL | 284 | $3,096 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 12 | $2,719 |
| Upper gastrointestinal endoscopy with biopsy | 166 | $1,696 |
| New patient visit (45+ min) | 215 | $138 |
| Return visit (30+ min) | 255 | $131 |
| Injection, propofol, 10 mg | 12 | $70 |
| 2024 | 944 | 6 | 41 | $7,849 |
| 2023 | 1,189 | 7 | 51 | $9,733 |
| 2022 | 1,380 | 5 | 48 | $9,336 |
| 2021 | 1,273 | 5 | 53 | $6,376 |
| 2020 | 871 | 5 | 45 | $5,210 |
| 2019 | 963 | 7 | 48 | $7,629 |
| 2018 | 1,246 | 7 | 47 | $30,965 |
See the largest Medicaid services in earlier years
2023
| COLONOSCOPY W/LESION REMOVAL | 249 | $2,506 |
| Upper gastrointestinal endoscopy with biopsy | 249 | $2,395 |
| Return visit (30+ min) | 280 | $1,585 |
| New patient visit (45+ min) | 344 | $1,443 |
| Injection, propofol, 10 mg | 26 | $1,060 |
| Lidocaine injection | 13 | $745 |
| DIAGNOSTIC COLONOSCOPY | 28 | $0 |
2022
| COLONOSCOPY W/LESION REMOVAL | 324 | $3,183 |
| Upper gastrointestinal endoscopy with biopsy | 237 | $2,883 |
| New patient visit (45+ min) | 441 | $2,517 |
| Return visit (30+ min) | 314 | $752 |
| DIAGNOSTIC COLONOSCOPY | 64 | $0 |
2021
| Upper gastrointestinal endoscopy with biopsy | 186 | $1,930 |
| COLONOSCOPY W/LESION REMOVAL | 281 | $1,781 |
| Return visit (30+ min) | 393 | $1,498 |
| New patient visit (45+ min) | 397 | $1,166 |
| DIAGNOSTIC COLONOSCOPY | 16 | $0 |
2020
| Return visit (30+ min) | 353 | $2,339 |
| COLONOSCOPY W/LESION REMOVAL | 85 | $925 |
| Upper gastrointestinal endoscopy with biopsy | 117 | $860 |
| New patient visit (45+ min) | 133 | $739 |
| New patient visit (30+ min) | 183 | $347 |
2019
| New patient visit (45+ min) | 329 | $2,687 |
| Return visit (30+ min) | 353 | $2,266 |
| COLONOSCOPY W/LESION REMOVAL | 160 | $1,382 |
| Upper gastrointestinal endoscopy with biopsy | 56 | $880 |
| Short return visit (20+ min) | 26 | $285 |
| DIAGNOSTIC COLONOSCOPY | 15 | $129 |
| COLONOSCOPY AND BIOPSY | 24 | $0 |
2018
| New patient visit (45+ min) | 392 | $11,273 |
| COLONOSCOPY W/LESION REMOVAL | 234 | $7,196 |
| Short return visit (20+ min) | 304 | $4,395 |
| Upper gastrointestinal endoscopy with biopsy | 151 | $4,241 |
| Return visit (30+ min) | 106 | $2,101 |
| DIAGNOSTIC COLONOSCOPY | 41 | $1,719 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 18 | $41 |
Drugs they prescribed that Part D paid
$1,729,465
Pharmacies billed $1,729,465 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 850) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
590 generic and 260 brand-name prescriptions · $1,729,465 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 50 | $1,326,649 | $26,533 |
| Vemlidy | 31 | $62,797 | $2,026 |
| Creon | 12 | $60,216 | $5,018 |
| Mesalamine | 53 | $32,743 | $618 |
| Linzess | 18 | $14,631 | $813 |
See all 18 drugs
| Stelara | 50 | $1,326,649 | $26,533 |
| Vemlidy | 31 | $62,797 | $2,026 |
| Creon | 12 | $60,216 | $5,018 |
| Mesalamine | 53 | $32,743 | $618 |
| Linzess | 18 | $14,631 | $813 |
| Colesevelam | 22 | $8,236 | $374 |
| Gavilyte-G | 164 | $2,346 | $14 |
| Sod Sulf-Potass Sulf-Mag Sulf | 36 | $2,233 | $62 |
| Esomeprazole Magnesium | 14 | $989 | $71 |
| Gavilyte-C | 57 | $785 | $14 |
| Peg-3350 and Electrolytes | 54 | $781 | $14 |
| Diphenoxylate-Atropine | 19 | $633 | $33 |
| Peg 3350-Electrolyte | 27 | $555 | $21 |
| Pantoprazole | 45 | $502 | $11 |
| Lubiprostone | 11 | $495 | $45 |
| Omeprazole | 68 | $460 | $7 |
| Sucralfate | 11 | $276 | $25 |
| Famotidine | 25 | $262 | $10 |
Year by year
| 2024 | 850 | 415 | 0% (0) | 31% | $1,729,465 |
| 2023 | 740 | 283 | 0% (0) | None | $2,013,632 |
| 2022 | 834 | 350 | None | None | $1,335,926 |
| 2021 | 732 | 254 | None | None | $1,043,385 |
| 2020 | 625 | 220 | 0% (0) | None | $1,111,576 |
| 2019 | 592 | 217 | 0% (0) | 34% | $975,389 |
| 2018 | 803 | 296 | 0% (0) | None | $544,035 |
| 2017 | 880 | 272 | 0% (0) | None | $509,043 |
| 2016 | 879 | 274 | 0% (0) | 36% | $662,567 |
| 2015 | 619 | 194 | 0% (0) | None | $394,222 |
| 2014 | 94 | 52 | 0% (0) | 34% | $24,496 |
| 2013 | 42 | 28 | 0% (0) | 26% | $19,526 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Stelara | 61 | $1,698,472 | $27,844 |
| Creon | 12 | $60,380 | $5,032 |
| Mesalamine | 52 | $51,529 | $991 |
| Vemlidy | 24 | $35,627 | $1,484 |
| Linzess | 20 | $13,128 | $656 |
| Colesevelam | 25 | $8,887 | $355 |
| Dexilant | 13 | $4,409 | $339 |
| Gavilyte-G | 151 | $2,461 | $16 |
| Pantoprazole | 71 | $1,465 | $21 |
| Sod Sulf-Potass Sulf-Mag Sulf | 17 | $1,398 | $82 |
| Diphenoxylate-Atropine | 17 | $1,288 | $76 |
| Omeprazole | 66 | $961 | $15 |
| Peg 3350-Electrolyte | 21 | $563 | $27 |
| Famotidine | 15 | $332 | $22 |
| Gavilyte-C | 16 | $251 | $16 |
| Ondansetron | 12 | $170 | $14 |
2022: 18 drugs
| Stelara | 39 | $1,049,328 | $26,906 |
| Humira(Cf) | 12 | $82,597 | $6,883 |
| Mesalamine | 45 | $42,610 | $947 |
| Creon | 16 | $41,908 | $2,619 |
| Vemlidy | 25 | $34,875 | $1,395 |
| Colesevelam | 18 | $10,597 | $589 |
| Dexilant | 23 | $10,171 | $442 |
| Linzess | 17 | $9,439 | $555 |
| Lubiprostone | 13 | $3,231 | $249 |
| Gavilyte-G | 138 | $2,009 | $15 |
| Pantoprazole | 105 | $1,402 | $13 |
| Peg 3350-Electrolyte | 44 | $939 | $21 |
| Omeprazole | 72 | $818 | $11 |
| Ondansetron Odt | 15 | $744 | $50 |
| Peg-3350 and Electrolytes | 44 | $577 | $13 |
| Gavilyte-C | 33 | $525 | $16 |
| Famotidine | 25 | $460 | $18 |
| Sucralfate | 13 | $447 | $34 |
2021: 21 drugs
| Stelara | 32 | $823,268 | $25,727 |
| Humira(Cf) | 12 | $75,632 | $6,303 |
| Vemlidy | 25 | $32,638 | $1,306 |
| Mesalamine | 35 | $17,132 | $489 |
| Colesevelam | 22 | $13,484 | $613 |
| Linzess | 27 | $13,081 | $484 |
| Welchol | 15 | $9,934 | $662 |
| Dexilant | 15 | $8,395 | $560 |
| Sucralfate | 12 | $3,439 | $287 |
| Mercaptopurine | 13 | $1,723 | $133 |
| Diphenoxylate-Atropine | 14 | $1,594 | $114 |
| Pantoprazole | 84 | $1,426 | $17 |
| Peg 3350-Electrolyte | 72 | $1,327 | $18 |
| Famotidine | 58 | $1,183 | $20 |
| Omeprazole | 73 | $1,088 | $15 |
| Dicyclomine | 22 | $570 | $26 |
| Ondansetron | 20 | $555 | $28 |
| Ondansetron Odt | 12 | $420 | $35 |
| Gavilyte-G | 29 | $382 | $13 |
| Peg-3350 and Electrolytes | 29 | $325 | $11 |
| Gavilyte-C | 16 | $210 | $13 |
2020: 16 drugs
| Stelara | 37 | $900,016 | $24,325 |
| Humira | 12 | $68,984 | $5,749 |
| Vemlidy | 24 | $29,430 | $1,226 |
| Mesalamine | 20 | $20,804 | $1,040 |
| Colesevelam | 12 | $14,314 | $1,193 |
| Linzess | 27 | $12,510 | $463 |
| Dexilant | 19 | $11,895 | $626 |
| Welchol | 16 | $11,297 | $706 |
| Sucralfate | 16 | $2,749 | $172 |
| Peg 3350-Electrolyte | 69 | $1,027 | $15 |
| Pantoprazole | 61 | $990 | $16 |
| Omeprazole | 88 | $943 | $11 |
| Gavilyte-N | 47 | $646 | $14 |
| Dicyclomine | 25 | $559 | $22 |
| Azathioprine | 11 | $416 | $38 |
| Famotidine | 16 | $318 | $20 |
2019: 14 drugs
| Stelara | 29 | $655,040 | $22,588 |
| Humira | 12 | $62,741 | $5,228 |
| Vemlidy | 20 | $23,229 | $1,161 |
| Mesalamine | 16 | $14,599 | $912 |
| Linzess | 33 | $14,491 | $439 |
| Entecavir | 12 | $11,724 | $977 |
| Welchol | 17 | $11,612 | $683 |
| Gavilyte-N | 65 | $1,100 | $17 |
| Sucralfate | 22 | $962 | $44 |
| Omeprazole | 89 | $886 | $10 |
| Pantoprazole | 56 | $835 | $15 |
| Peg 3350-Electrolyte | 49 | $798 | $16 |
| Sulfasalazine | 13 | $277 | $21 |
| Famotidine | 22 | $238 | $11 |
2018: 19 drugs
| Stelara | 12 | $252,288 | $21,024 |
| Welchol | 32 | $22,400 | $700 |
| Linzess | 35 | $14,244 | $407 |
| Vemlidy | 11 | $12,235 | $1,112 |
| Nexium | 14 | $11,409 | $815 |
| Entecavir | 11 | $10,400 | $945 |
| Mesalamine | 16 | $10,004 | $625 |
| Budesonide Ec | 14 | $9,853 | $704 |
| Colesevelam | 13 | $9,493 | $730 |
| Trulance | 11 | $5,528 | $503 |
| Dexilant | 11 | $4,020 | $365 |
| Peg 3350-Electrolyte | 114 | $1,996 | $18 |
| Gavilyte-N | 92 | $1,558 | $17 |
| Omeprazole | 104 | $853 | $8 |
| Pantoprazole | 81 | $847 | $10 |
| Sucralfate | 18 | $398 | $22 |
| Azathioprine | 13 | $365 | $28 |
| Famotidine | 47 | $299 | $6 |
| Ondansetron | 15 | $249 | $17 |
2017: 19 drugs
| Humira | 17 | $89,155 | $5,244 |
| Welchol | 52 | $31,734 | $610 |
| Creon | 15 | $16,547 | $1,103 |
| Canasa | 16 | $15,466 | $967 |
| Lialda | 13 | $14,392 | $1,107 |
| Nexium | 23 | $13,672 | $594 |
| Linzess | 36 | $13,171 | $366 |
| Budesonide Ec | 11 | $10,189 | $926 |
| Pantoprazole | 132 | $1,563 | $12 |
| Peg 3350-Electrolyte | 109 | $1,545 | $14 |
| Gavilyte-N | 56 | $947 | $17 |
| Methotrexate | 18 | $896 | $50 |
| Omeprazole | 92 | $589 | $6 |
| Sucralfate | 25 | $570 | $23 |
| Ondansetron | 24 | $405 | $17 |
| Famotidine | 46 | $286 | $6 |
| Prednisone | 11 | $191 | $17 |
| Polyethylene Glycol 3350 | 12 | $180 | $15 |
| Dicyclomine | 16 | $129 | $8 |
2016: 19 drugs
| Humira | 32 | $158,591 | $4,956 |
| Creon | 22 | $43,618 | $1,983 |
| Nexium | 28 | $12,219 | $436 |
| Welchol | 26 | $11,717 | $451 |
| Budesonide Ec | 13 | $10,275 | $790 |
| Linzess | 21 | $6,815 | $325 |
| Pantoprazole | 170 | $1,838 | $11 |
| Peg 3350-Electrolyte | 83 | $1,359 | $16 |
| Gavilyte-N | 69 | $1,147 | $17 |
| Suprep | 13 | $1,080 | $83 |
| Sucralfate | 26 | $585 | $22 |
| Clarithromycin | 11 | $555 | $50 |
| Omeprazole | 77 | $535 | $7 |
| Methotrexate | 12 | $495 | $41 |
| Famotidine | 49 | $348 | $7 |
| Ondansetron | 18 | $285 | $16 |
| Prednisone | 11 | $220 | $20 |
| Amitriptyline | 24 | $211 | $9 |
| Amoxicillin | 11 | $106 | $10 |
2015: 13 drugs
| Budesonide Ec | 17 | $10,481 | $617 |
| Nexium | 24 | $9,976 | $416 |
| Welchol | 18 | $7,655 | $425 |
| Pantoprazole | 130 | $1,419 | $11 |
| Suprep | 17 | $1,387 | $82 |
| Gavilyte-N | 55 | $1,070 | $19 |
| Lansoprazole | 14 | $1,051 | $75 |
| Peg 3350-Electrolyte | 52 | $937 | $18 |
| Polyethylene Glycol 3350 | 31 | $679 | $22 |
| Omeprazole | 60 | $586 | $10 |
| Trilyte With Flavor Packets | 13 | $240 | $18 |
| Ranitidine | 13 | $93 | $7 |
| Famotidine | 13 | $79 | $6 |
2014: 3 drugs
| Peg-3350 | 15 | $305 | $20 |
| Omeprazole | 18 | $227 | $13 |
| Pantoprazole | 16 | $221 | $14 |
2013: 1 drug
| Ciprofloxacin | 16 | $69 | $4 |
Money from drug and device companies
$3,164 in 2025
| 2025 | 18 | 112 | None | $3,164 |
| 2024 | 14 | 102 | None | $2,764 |
| 2023 | 15 | 105 | None | $2,998 |
| 2022 | 10 | 93 | None | $2,122 |
| 2021 | 12 | 82 | None | $1,633 |
| 2020 | 8 | 34 | None | $814 |
| 2019 | 8 | 47 | None | $661 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $756 | 30 payments
|
| Janssen Biotech | Tremfya | $702 | 16 payments
|
| Lilly USA | Omvoh | $534 | 15 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $349 | 17 payments
|
| Ardelyx | Ibsrela | $214 | 8 payments
|
| Aimmune Therapeutics | Zenpep | $82 | 3 payments
|
See all 112 published payments
| Pfizer | Meals · 2025-12-12 | Velsipity | $15 |
| Abbvie | Meals · 2025-12-11 | Rinvoq | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-10 | Eohilia | $43 |
| Ardelyx | Meals · 2025-12-09 | Ibsrela | $30 |
| Novo Nordisk | Meals · 2025-12-08 | Wegovy | $22 |
| Aimmune Therapeutics | Meals · 2025-12-04 | Zenpep | $28 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-03 | Iqirvo | $26 |
| QOL Medical | Meals · 2025-11-21 | Sucraid | $19 |
| Abbvie | Meals · 2025-11-19 | Skyrizi | $26 |
| Pfizer | Meals · 2025-11-18 | Velsipity | $21 |
| Pfizer | Meals · 2025-11-06 | Velsipity | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-05 | Entyvio | $21 |
| Abbvie | Meals · 2025-11-04 | Skyrizi | $25 |
| Aimmune Therapeutics | Meals · 2025-11-04 | Zenpep | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-29 | Entyvio | $21 |
| Janssen Biotech | Meals · 2025-10-24 | Tremfya | $36 |
| QOL Medical | Meals · 2025-10-23 | Sucraid | $26 |
| Ardelyx | Meals · 2025-10-20 | Ibsrela | $29 |
| Janssen Biotech | Meals · 2025-10-15 | Tremfya | $32 |
| Pfizer | Meals · 2025-10-14 | Velsipity | $21 |
| Abbvie | Meals · 2025-10-10 | Rinvoq | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-09 | Entyvio | $19 |
| Ipsen Biopharmaceuticals | Meals · 2025-10-08 | Iqirvo | $28 |
| Genzyme | Meals · 2025-10-08 | Dupixent | $42 |
| Janssen Biotech | Meals · 2025-10-02 | Tremfya | $126 |
| Abbvie | Meals · 2025-09-25 | Linzess | $33 |
| Intercept Pharmaceuticals | Meals · 2025-09-25 | Ocaliva | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-19 | Entyvio | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-18 | Entyvio | $28 |
| Abbvie | Meals · 2025-09-17 | Rinvoq | $20 |
| Aimmune Therapeutics | Meals · 2025-09-16 | Zenpep | $29 |
| Abbvie | Meals · 2025-09-09 | Creon | $19 |
| Abbvie | Meals · 2025-09-09 | Rinvoq | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-29 | Entyvio | $17 |
| Abbvie | Meals · 2025-08-27 | Rinvoq | $24 |
| Ardelyx | Meals · 2025-08-25 | Ibsrela | $25 |
| Abbvie | Meals · 2025-08-22 | Rinvoq | $23 |
| QOL Medical | Meals · 2025-08-19 | Sucraid | $23 |
| Abbvie | Meals · 2025-08-14 | Skyrizi | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-13 | Entyvio | $21 |
| Abbvie | Meals · 2025-08-12 | Skyrizi | $22 |
| Ardelyx | Meals · 2025-07-29 | Ibsrela | $31 |
| Intercept Pharmaceuticals | Meals · 2025-07-25 | Ocaliva | $17 |
| Janssen Biotech | Meals · 2025-07-24 | Tremfya | $35 |
| Lilly USA | Meals · 2025-07-21 | Omvoh | $35 |
| Abbvie | Meals · 2025-07-18 | Rinvoq | $22 |
| Abbvie | Meals · 2025-07-16 | Rinvoq | $23 |
| Lilly USA | Meals · 2025-07-15 | Omvoh | $32 |
| Abbvie | Meals · 2025-07-08 | Creon | $16 |
| Abbvie | Meals · 2025-07-01 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-06-26 | Tremfya | $33 |
| Ardelyx | Meals · 2025-06-24 | Ibsrela | $28 |
| Lilly USA | Meals · 2025-06-23 | Omvoh | $32 |
| Abbvie | Meals · 2025-06-13 | Rinvoq | $27 |
| Abbvie | Meals · 2025-06-12 | Rinvoq | $23 |
| Janssen Biotech | Meals · 2025-06-11 | Tremfya | $30 |
| Lilly USA | Meals · 2025-06-09 | Omvoh | $22 |
| Janssen Biotech | Meals · 2025-06-06 | Tremfya | $30 |
| Abbvie | Meals · 2025-06-05 | Linzess | $13 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-04 | Entyvio | $26 |
| Abbvie | Meals · 2025-05-29 | Skyrizi | $23 |
| Gilead Sciences | Meals · 2025-05-28 | None | $33 |
| Ardelyx | Meals · 2025-05-27 | Ibsrela | $24 |
| Gilead Sciences | Meals · 2025-05-23 | None | $31 |
| Lilly USA | Meals · 2025-05-21 | Omvoh | $106 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-21 | Entyvio | $19 |
| Abbvie | Meals · 2025-05-20 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-05-15 | Tremfya | $32 |
| Vivus | Meals · 2025-05-13 | Pancreaze | $15 |
| Abbvie | Meals · 2025-05-12 | Rinvoq | $20 |
| Lilly USA | Meals · 2025-05-09 | Omvoh | $24 |
| Abbvie | Meals · 2025-05-08 | Rinvoq | $34 |
| Lilly USA | Meals · 2025-05-02 | Omvoh | $34 |
| Janssen Biotech | Meals · 2025-05-01 | Tremfya | $35 |
| Braintree Laboratories | Meals · 2025-04-30 | Sutab | $21 |
| Abbvie | Meals · 2025-04-29 | Rinvoq | $29 |
| Janssen Biotech | Meals · 2025-04-24 | Tremfya | $126 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-21 | Xifaxan | $23 |
| Celltrion USA | Meals · 2025-04-16 | Vegzelma | $18 |
| Abbvie | Meals · 2025-04-15 | Rinvoq | $33 |
| Intercept Pharmaceuticals | Meals · 2025-04-11 | Ocaliva | $17 |
| Janssen Biotech | Meals · 2025-04-10 | Tremfya | $30 |
| Lilly USA | Meals · 2025-04-08 | Omvoh | $23 |
| Lilly USA | Meals · 2025-03-28 | Omvoh | $35 |
| Ardelyx | Meals · 2025-03-27 | Ibsrela | $26 |
| Lilly USA | Meals · 2025-03-24 | Omvoh | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-20 | Entyvio | $24 |
| Abbvie | Meals · 2025-03-18 | Rinvoq | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-14 | Entyvio | $12 |
| Janssen Biotech | Meals · 2025-03-13 | Tremfya | $33 |
| Braintree Laboratories | Meals · 2025-03-12 | Suflave | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-26 | Entyvio | $11 |
| Lilly USA | Meals · 2025-02-25 | Omvoh | $33 |
| Lilly USA | Meals · 2025-02-25 | Omvoh | $30 |
| Abbvie | Meals · 2025-02-24 | Rinvoq | $28 |
| Ardelyx | Meals · 2025-02-20 | Ibsrela | $20 |
| Abbvie | Meals · 2025-02-19 | Skyrizi | $32 |
| Janssen Biotech | Meals · 2025-02-18 | Tremfya | $34 |
| Janssen Biotech | Meals · 2025-02-13 | Tremfya | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-11 | Entyvio | $18 |
| Abbvie | Meals · 2025-02-04 | Rinvoq | $26 |
| Abbvie | Meals · 2025-01-31 | Rinvoq | $29 |
| Janssen Biotech | Meals · 2025-01-29 | Tremfya | $26 |
| Lilly USA | Meals · 2025-01-29 | Omvoh | $32 |
| Lilly USA | Meals · 2025-01-24 | Omvoh | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-21 | Entyvio | $11 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-17 | Entyvio | $23 |
| Lilly USA | Meals · 2025-01-15 | Omvoh | $33 |
| Vivus | Meals · 2025-01-14 | Pancreaze | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-08 | Entyvio | $12 |
| Janssen Biotech | Meals · 2025-01-07 | Tremfya | $39 |
| Madrigal Pharmaceuticals | Meals · 2025-01-06 | Rezdiffra | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,764
| Abbvie | Rinvoq | $747 | 29 payments
|
| Janssen Biotech | Tremfya | $733 | 23 payments
|
| Lilly USA | Omvoh | $522 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $215 | 12 payments
|
| QOL Medical | Sucraid | $166 | 7 payments
|
| Celgene | Zeposia | $67 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $67 | 3 payments
|
| Pfizer | Xeljanz | $64 | 3 payments
|
| Genzyme | Dupixent | $41 | 1 payment
|
| Celltrion USA | Zymfentra | $39 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $39 | 2 payments
|
| Biocon Biologics | Hulio | $29 | 1 payment
|
| Boston Scientific | Captivator II | $21 | 1 payment
|
| Vivus | Pancreaze | $15 | 1 payment
|
2023: $2,998
| AbbVie | Skyrizi | $984 | 32 payments
|
| Janssen Biotech | Stelara | $499 | 13 payments
|
| Celgene | Zeposia | $420 | 21 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $244 | 12 payments
|
| Genzyme | Dupixent | $184 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $164 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $105 | 5 payments
|
| QOL Medical | Sucraid | $81 | 4 payments
|
| Gilead Sciences | None | $75 | 2 payments
|
| Pfizer | Xeljanz | $65 | 3 payments
|
| Nestle Healthcare Nutrition | Zenpep | $51 | 2 payments
|
| Fresenius Kabi USA | Idacio | $45 | 2 payments
|
| Medtronic | Gi Genius | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $26 | 1 payment
|
| Lilly USA | None | $24 | 1 payment
|
2022: $2,122
| Abbvie | Rinvoq | $893 | 35 payments
|
| Janssen Biotech | Stelara | $346 | 16 payments
|
| Celgene | Zeposia | $279 | 18 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $228 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $117 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $108 | 1 payment
|
| Pfizer | Xeljanz | $61 | 3 payments
|
| Genzyme | Dupixent | $39 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $28 | 1 payment
|
| Braintree Laboratories | Sutab | $23 | 1 payment
|
2021: $1,633
| AbbVie | Humira | $570 | 26 payments
|
| Janssen Biotech | Stelara | $466 | 26 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $254 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $97 | 4 payments
|
| Braintree Laboratories | Sutab | $56 | 3 payments
|
| RedHill Biopharma | Movantik | $43 | 2 payments
|
| Celgene | Zeposia | $42 | 2 payments
|
| Ferring Pharmaceuticals | Clenpiq | $40 | 2 payments
|
| Pfizer | Xeljanz | $18 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $17 | 1 payment
|
| Gilead Sciences | None | $16 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $13 | 1 payment
|
2020: $814
| AbbVie | Humira | $455 | 17 payments
|
| Janssen Biotech | Stelara | $128 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $91 | 5 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $49 | 2 payments
|
| Gilead Sciences | None | $39 | 1 payment
|
| Pfizer | Xeljanz | $20 | 1 payment
|
| Endo Pharmaceuticals | Nascobal | $18 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $14 | 1 payment
|
2019: $661
| Janssen Biotech | Stelara | $135 | 11 payments
|
| Pfizer | Xeljanz | $129 | 10 payments
|
| Gilead Sciences | None | $114 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $98 | 7 payments
|
| AbbVie | Mavyret | $72 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $70 | 4 payments
|
| Daiichi Sankyo | Injectafer | $25 | 1 payment
|
| Endo Pharmaceuticals | Nascobal | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205161130
- Licence
- CA A111820California A111820: Current · expires 2028-04-30
- Group
- East Bay Center for Digestive Health Medical Associates Inc · Alameda Health System
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Frank H Ogawa Plz Ste 355, Oakland, CA, 94612
- NPI first listed
- 2009-10-09
- NPI last updated
- 2023-11-20
- NPI record certified
- 2023-11-20
This is when the NPI record was last certified, not a medical board exam.